

Hugh S Griffith Chief Executive Officer T: +44 (0) 131 248 3660 E: info@nucana.com

W: www.nucana.com

Edinburgh, U.K., 30th March 2016

## NuCana's Chief Scientific Officer, Professor Chris McGuigan

Edinburgh, U.K., 30th March 2016: It is with profound sadness that NuCana marks the passing of our friend and colleague Professor Chris McGuigan on 11th March 2016. Professor McGuigan was Chief Scientific Officer for NuCana and the inventor of the ProTide technology.

Professor McGuigan was Professor of Medicinal Chemistry at Cardiff University School of Pharmacy and Pharmaceutical Sciences and Chair of the Life Sciences Hub Wales. Professor McGuigan has made an extensive contribution to medical science with over 30 years' experience in drug discovery and development. A world renowned expert in nucleotides coupled with an acute business acumen led to four new medicines entering clinical development. NuCana is committed to ensuring Professor McGuigan's pioneering research translates into more effective and safer medicines for patients with cancer.

Hugh Griffith, NuCana's Chief Executive Officer, said: "We are deeply saddened by Chris's untimely passing. He had achieved such a huge amount in the field of medicinal chemistry and there is no doubt that his legacy will remain through his work and discoveries. We extend our sincere condolences to his family, friends and colleagues."

## About NuCana

NuCana® is a rapidly growing, clinical stage biopharmaceutical company with a broad development portfolio of novel anti-cancer medicines. The Company's proprietary ProTide technology has the potential to set new benchmarks in efficacy and safety with its treatments that are specifically designed to overcome key cancer resistance mechanisms. Acelarin® is NuCana's lead medicine and has achieved exceptional levels of disease control in a broad range of patients with advanced, rapidly progressing solid tumours. NuCana's second ProTide, NUC-3373, has just entered clinical development and several more ProTides are progressing through IND enabling programmes.

For more information, please visit: www.nucana.com

For more information, please contact
Hugh S. Griffith
CEO
NuCana
+44 131 248 3660
info@nucana.com
www.nucana.com

Cont'd